These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 15793108)

  • 1. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection.
    Jaruratanasirikul S; Sriwiriyajan S; Punyo J
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1337-9. PubMed ID: 15793108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of meropenem in critically ill patients with ventilator-associated pneumonia.
    Jaruratanasirikul S; Kositpantawong N; Jullangkoon M; Aeinlang N; Wongpoowarak W
    J Med Assoc Thai; 2013 Oct; 96(10):1283-9. PubMed ID: 24350408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia.
    Jaruratanasirikul S; Limapichat T; Jullangkoon M; Aeinlang N; Ingviya N; Wongpoowarak W
    Int J Antimicrob Agents; 2011 Sep; 38(3):231-6. PubMed ID: 21726984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection.
    Jaruratanasirikul S; Sriwiriyajan S
    J Antimicrob Chemother; 2003 Sep; 52(3):518-21. PubMed ID: 12917242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion.
    Jaruratanasirikul S; Sudsai T
    J Antimicrob Chemother; 2009 Mar; 63(3):560-3. PubMed ID: 19153079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli.
    Lorente L; Lorenzo L; Martín MM; Jiménez A; Mora ML
    Ann Pharmacother; 2006 Feb; 40(2):219-23. PubMed ID: 16449546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.
    Kim A; Kuti JL; Nicolau DP
    Clin Ther; 2009 Nov; 31(11):2765-78. PubMed ID: 20110018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection.
    Kongthavonsakul K; Lucksiri A; Eakanunkul S; Roongjang S; Issaranggoon Na Ayuthaya S; Oberdorfer P
    Int J Antimicrob Agents; 2016 Aug; 48(2):151-7. PubMed ID: 27345269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
    Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB
    Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study.
    Frippiat F; Musuamba FT; Seidel L; Albert A; Denooz R; Charlier C; Van Bambeke F; Wallemacq P; Descy J; Lambermont B; Layios N; Damas P; Moutschen M
    J Antimicrob Chemother; 2015 Jan; 70(1):207-16. PubMed ID: 25216821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental verification of the efficacy of optimized two-step infusion therapy with meropenem using an in vitro pharmacodynamic model and Monte Carlo simulation.
    Eguchi K; Kanazawa K; Shimizudani T; Kanemitsu K; Kaku M
    J Infect Chemother; 2010 Feb; 16(1):1-9. PubMed ID: 20072800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
    Sumitani Y; Kobayashi Y
    Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS; Frei CR
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic/Pharmacodynamic Analysis of Meropenem for the Treatment of Nosocomial Pneumonia in Intracerebral Hemorrhage Patients by Monte Carlo Simulation.
    Kong L; Tang Y; Zhang X; Lu G; Yu M; Shi Q; Wu X
    Ann Pharmacother; 2017 Nov; 51(11):970-975. PubMed ID: 28677407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of short versus extended infusion meropenem dosing in critically ill patients: a pilot study.
    Langan KM; Jacob J; Li J; Nation RL; Bellomo R; Howden B; Johnson PD
    Crit Care Resusc; 2014 Sep; 16(3):190-6. PubMed ID: 25161021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.
    Kuti JL; Dandekar PK; Nightingale CH; Nicolau DP
    J Clin Pharmacol; 2003 Oct; 43(10):1116-23. PubMed ID: 14517194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of meropenem in pancreatic juice and site-specific pharmacodynamic target attainment against Gram-negative bacteria: dosing considerations.
    Kondo N; Ikawa K; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Ohge H; Morikawa N; Sueda T
    Pancreatology; 2014; 14(2):95-9. PubMed ID: 24650961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
    Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients.
    Cheatham SC; Kays MB; Smith DW; Wack MF; Sowinski KM
    Pharmacotherapy; 2008 Jun; 28(6):691-8. PubMed ID: 18503396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics of doripenem in critically ill patients with ventilator-associated Gram-negative bacilli pneumonia.
    Jaruratanasirikul S; Wongpoowarak W; Kositpantawong N; Aeinlang N; Jullangkoon M
    Int J Antimicrob Agents; 2012 Nov; 40(5):434-9. PubMed ID: 22959555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.